Welcome to our dedicated page for Nephros news (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros stock.
Nephros Inc. reports developments in water technology for medical and commercial markets, with emphasis on point-of-use filtration, waterborne pathogen risk reduction, and water management support. Company news commonly covers quarterly financial results, programmatic revenue trends, service offerings, customer education, and product adoption across healthcare facilities and other complex buildings.
Updates also include expansions of Nephros' water safety capabilities, regional market initiatives, and the Nephros Water Institute, an education effort focused on water quality, infection prevention, regulatory readiness, and emergency preparedness for compromised water events.
Nephros (Nasdaq: NEPH), a water technology company specializing in filtration solutions for healthcare and commercial markets, announced it will release its third-quarter 2024 financial results on Thursday, November 7, 2024, after market close. The company will host a conference call at 4:30pm ET the same day. Participants can join via domestic access (1-844-808-7106) or international access (1-412-317-5285). An audio archive will be available on the Nephros Investor Relations page, with replay access until November 14, 2024.
Nephros (Nasdaq: NEPH) has launched the HydraGuard 20" UltraFilter, expanding its filtration technology portfolio. The new filter offers higher-volume capacity and flow rate while removing bacteria, viruses, and endotoxins. This product enables Nephros to enter new markets, particularly medical device manufacturing and pharmaceutical production, supporting compliance with water quality standards like ANSI/AAMI ST108.
The filter builds upon existing HydraGuard technology, previously to dialysis water purification, and provides exceptional retention of microbiological contaminants through size exclusion, offering more reliable performance compared to charged membranes.
Nephros, Inc. (Nasdaq: NEPH), a leader in advanced filtration technology, has responded rapidly to the recent hurricanes Helene and Milton that devastated parts of the southeastern United States. The company provided important water filtration solutions to multiple healthcare and nursing care facilities affected by the storms, ensuring a safe water supply for patients and staff during recovery efforts.
Nephros has shipped a significant number of filters, responding after hours and delivering next day to both federal and local disaster response partners. Their solutions have been deployed across multiple states and facility types, including:
- Florida hospitals where Nephros in-line filters were previously installed
- North Carolina nursing and care facilities where point-of-use filters provided immediate protection against bacteria
The company's ability to act quickly in disaster response situations underscores its commitment to clean water access, offering an effective alternative to typical emergency water sources.
Nephros (NEPH) reported Q2 2024 financial results with net revenue of $3.3 million, an 8% decrease from Q2 2023. However, programmatic revenue increased by 8% year-over-year, driven by over 300 new accounts added in the past 12 months. The company reported a net loss of $0.3 million, an improvement from $0.4 million in Q2 2023. Adjusted EBITDA was ($133,000), compared to ($183,000) in the prior year.
CEO Robert Banks highlighted growth in the core programmatic business but noted a decline in emergency response sales. The company is developing new business models to address challenges in filter changeout schedules. As of June 30, 2024, Nephros had cash and cash equivalents of $3.1 million.
Nephros Inc (Nasdaq: NEPH), a leading water technology company, has announced its schedule for the second quarter 2024 financial results conference call. The company will file its Q2 financial results on Thursday, August 8, 2024 after market close and host a conference call at 4:30pm ET the same day. Participants can join the call using the following dial-in numbers:
- Domestic access: 1 (844) 808-7106
- International access: 1 (412) 317-5285
An audio archive will be available on the Nephros Investor Relations page shortly after the call. A replay will also be accessible until August 15, 2024, using specific replay access codes for domestic and international callers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.